WO2002011793A1 - Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection - Google Patents

Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection Download PDF

Info

Publication number
WO2002011793A1
WO2002011793A1 PCT/JP2001/006782 JP0106782W WO0211793A1 WO 2002011793 A1 WO2002011793 A1 WO 2002011793A1 JP 0106782 W JP0106782 W JP 0106782W WO 0211793 A1 WO0211793 A1 WO 0211793A1
Authority
WO
WIPO (PCT)
Prior art keywords
syringe
sliding valve
slider
intermediate sliding
slide
Prior art date
Application number
PCT/JP2001/006782
Other languages
English (en)
Japanese (ja)
Inventor
Tetsuro Higashikawa
Kazuo Yanagisawa
Original Assignee
Medical Information Services, Inc.
Izumi Seimitsu, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Information Services, Inc., Izumi Seimitsu, Inc. filed Critical Medical Information Services, Inc.
Publication of WO2002011793A1 publication Critical patent/WO2002011793A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/284—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle comprising means for injection of two or more media, e.g. by mixing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M2005/1787—Syringes for sequential delivery of fluids, e.g. first medicament and then flushing liquid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
    • A61M5/286—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst
    • A61M2005/287—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst by displacing occluding plugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A61M2005/3132—Syringe barrels having flow passages for injection agents at the distal end of the barrel to bypass a sealing stopper after its displacement to this end due to internal pressure increase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
    • A61M5/286—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31596—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms comprising means for injection of two or more media, e.g. by mixing

Definitions

  • the present invention relates to a syringe for a syringe-type kit preparation, an intermediate slide valve for a syringe, and a syringe-type kit preparation capable of sequentially injecting two or more drugs in one operation without mixing the drugs.
  • Some syringe-type kit preparations can inject multiple drugs in a single operation.
  • treatment requires two or more drugs with different physical, chemical, or pharmacological properties, but cannot be used as a mixture due to problems such as stability (for example, an acidic drug and an Combination with a nervous system drug) or injecting a therapeutic agent (second agent) into the injection site, causing severe pain at the site of administration.
  • a drug is administered as a first drug.
  • the first agent is a local anesthetic such as lidocaine hydrochloride, such as osteoarthritis of the knee and shoulder periarthritis, and the effect of needle thickness, pH and osmotic pressure ratio are
  • lidocaine hydrochloride such as osteoarthritis of the knee and shoulder periarthritis
  • the effect of needle thickness, pH and osmotic pressure ratio are
  • it is widely used around the world, and it is widely used around the world for venous blood vessels, although it is widely used around the world, such as sodium hyaluronate, which may cause severe pain to the affected area of the patient due to poor medical procedures etc.
  • a typical example is a combination with an induction anesthetic (propofol), which is known to cause severe pain.
  • FIG. 12 shows a syringe-type key that can inject two drugs in one operation.
  • FIG. 3 is a model diagram showing an example of a kit preparation.
  • the syringe shown here has a syringe barrel having an injection needle connection part at one end and an opening at the other end, and a plunger inserted through the opening, wherein the injection needle in the syringe barrel is provided. Between the connecting part and the plunger, two or more partitioning parts (sliding valves) for dividing the internal space of the syringe cylinder into a plurality of chambers in a watertight manner are slidably provided.
  • the injection agent is stored in two or more chambers formed between the plungers, and the plunger moves to the injection needle side to allow the respective chambers to communicate with the injection needle connection portion (communication passage 1).
  • This is a kit preparation using an in-line sequential dispensing syringe provided with c)).
  • the first agent is filled with a reference numeral 5 in a watertight space defined by an injection cylinder 1, an intermediate sliding valve (middle stopper) 3 of the kit preparation, and a cap 4 at a syringe needle connection portion 1a of the injection cylinder 1. Have been.
  • Fig. 12 (b) is a cross-sectional view (model drawing) of the L-shaped part of Fig. 12 (a). Such a kit preparation is used prior to use, as shown in Fig. 12 (c).
  • the injection needle 7 is attached to the injection needle connection part 1a of the injection needle.
  • the air bubbles can be removed by operating the plunger operation section 2a with the injection needle side up.
  • the plunger operation section 2a is operated at this stage to reduce the amount of the first agent 5.
  • the injection needle 7 is pierced into the required injection site, and then the plunger operation section 2a is moved to the injection needle side to inject the first agent 5 (see FIG. 13 (a)). Thereafter, when the operation of the plunger operation section 2a is further continued, the second agent 6 is injected into the injection required site this time.
  • the intermediate sliding valve 3 moves toward the syringe needle and reaches the tip of the syringe barrel, but since the ⁇ ⁇ portion 3a provided on the intermediate sliding valve 3 contacts the syringe barrel bottom 1, the sliding valve is Since the communication channel 1c is bypassed without being in close contact with the syringe barrel bottom 1b, even if these sliding valves are moved to the syringe barrel bottom 1b side, the second valve 6 can be transferred to the injection needle 7. Supply passage is secured.
  • FIG. 13 (b) shows a state in which the operation of the plunger operation section 2a has been completed and the injection of the second agent 6 has been completed. Normally, the injection needle is removed from the required injection site in this state, but if the injection amount of the second agent 6 is to be reduced, the injection needle is pulled out of the injection site with the second agent 6 remaining in the syringe 1 May be.
  • the second agent 6 is confirmed at the site where the first agent 5 was injected. Since the second agent 6 is actually injected, painless or less painful injection can be performed even if the second agent 6 has a significantly different pH, osmotic pressure, temperature, etc. compared to the body fluid.
  • the syringe barrel 1 shown in FIGS. 12 and 13 is manufactured by processing a normal glass syringe barrel manufactured from a glass tube as a raw material. That is, the communication passage 1c is formed by heating and / or immediately after heating the corresponding portion where the communication passage 1c of the ordinary glass syringe is provided, or by vacuum suction from the outside of the syringe. The position of the communication passage 1c at that time is determined based on the needle-side surface of the finger grip 1d of the syringe barrel 1.
  • the accuracy of the position and the shape of the finger grip 1d is low in a general glass syringe, and the position accuracy of the communication passage 1c formed based on the finger grip 1d having the low position / shape accuracy is low.
  • the communication passage 1c must be formed at a position slightly away from the bottom 1b of the injection cylinder, and as a result, before the injection operation of the first agent 5 is completed.
  • the second agent 6 reaches the first agent 5 side through the communication passage 1c and is mixed with the first agent 5 for injection, or the injection of the first agent 5 has been completed.
  • the conventional syringe itself (without a communication passage) is used as the syringe itself.
  • a hollow portion is provided in the intermediate slide valve, and when the operation of injecting the pre-solution is completed, the pressure in the post-solution is changed to an intermediate value.
  • a technique has been proposed in which a part of a sliding valve is deformed to form a fluid passage between the side surface and the inner wall of a syringe cylinder (Japanese Patent Application Laid-Open No. H10-5057486). JP-A-10-80485).
  • the conditions for forming the liquid passage due to such deformation of the intermediate slide valve depend on the dynamic pressure applied to the intermediate slide valve and the flexibility of the material forming the intermediate slide valve. Not only when used in the ground or in extremely cold regions, but also depending on conditions such as how to apply force from the operator, the viscosity of the drug, the temperature, and the thickness of the injection needle used. The reliability was extremely low, and it was not possible to sufficiently meet the required performance of reliably injecting multiple drugs in a single injection operation.
  • an intermediate sliding valve S1 has a through hole S11 penetrating the front and rear thereof.
  • a closing body S12 made of plastic or the like is fitted in the through-hole S11 to close the through-hole S11.
  • the intermediate slide valve S1 moves to the injection needle side.
  • the intermediate slide valve S1 is provided at the center of the inner side of the bottom of the injection cylinder S3 needle side S31 toward the plunger operation side.
  • the closing body pushing member S 3 1 1 pushes out the closing body S 1 2 of the intermediate sliding valve S 1, and the closing body S 1 2 is formed of the intermediate sliding valve S 1 by the elastomeric property of the intermediate sliding valve S 1. Quickly moved to the rear storage section S13 of the closed body (Fig.
  • the intermediate sliding valve S 1 is at the moment when the closing body S 12 moves to the rear storage section S 13 of the closing body and the through hole S 11 is opened, that is, as shown in FIG. 14 (b). Then, the pressure for advancing forward is released, and the movement to the needle side is interrupted and ended. As a result, the needle for the drug solution S 4 existing in the space between the intermediate sliding valve S 1 and the bottom of the syringe barrel is released. The single and direct supply to is stopped, and the chemical solution S5 supplied through the through-hole S11 of the intermediate sliding valve S1 is gradually mixed and supplied to the needle. In other words, in the case of the syringe shown in Fig. 14, the performance as a syringe for kit preparations that requires certainty in injecting multiple drugs sequentially without being mixed by one injection operation is required. Can not be obtained.
  • the through hole S11 must be large enough to allow the closure S12 to move, and the dead volume of the closure extrusion member S311 is large, and the weight per kg of sodium hyaluronate etc. It is necessary to fill an extra chemical solution using expensive raw materials such as 500,000 to 600,000 yen, or injection of a predetermined amount becomes impossible.
  • the closing body pushing member S311 is provided so as to protrude toward the plunger operating side at the center of the inside of the bottom of the syringe needle S3 needle side S31, at least the syringe cylinder S3 is provided. It is necessary to be composed of two members, 32 and the needle-side bottom portion S31, and the price of the syringe is high. Furthermore, there is a concern that water vapor or sterilizing gas may enter from the joints of these members during the necessary sterilization after filling the drug, or a problem unique to a kit drug injector filled with a drug for a long time. In addition, there is a concern about leakage of liquid from these joints or invasion of various germs, and it is necessary to use a specially shaped injection cylinder as described above. It is very disadvantageous in cost because it cannot be used.
  • the present invention solves such a problem of the conventional technology, that is, using a conventional normal-shaped injection cylinder without a communication passage, a closing body extruding member, and a joint portion, reliably using two liquids.
  • the syringe for kit preparation of the present invention has an intermediate slide valve inside the injection cylinder, and a syringe-type kit preparation wherein at least the plunger operation side of the intermediate slide valve is filled with a drug solution.
  • the intermediate slide valve is in contact with the inner wall of the syringe barrel, and an annular lip that watertightly divides a space on the syringe needle side and a space on the plunger operation side of the intermediate slide valve, and a side of the syringe needle bypassing the annular lip.
  • a through-hole communicating the space with the plunger operation-side space, sealing means for sealing the through-hole, and the sealing when the intermediate sliding valve reaches the injection needle side end point or near the end point by injection operation.
  • a seal release means for releasing the injection.
  • the medicine can be sequentially and reliably injected sequentially using a conventional normal-shaped injection cylinder having no communication passage or a joint having a fear of liquid leakage or the like. Also, at this time, the material constituting the intermediate sliding valve is not unnecessarily frictionally pierced, so that there is no danger of dropout (coring, etc.) of a part of the material, and the safety is ensured.
  • the syringe for kit preparation of the present invention is the syringe for kit preparation according to claim 1, wherein the intermediate slide valve has an annular lip and a through hole.
  • the seal means and the seal release means project from the front of the intermediate sliding valve body toward the syringe needle, and the sealing means and the seal releasing means protrude forward from the syringe needle toward the syringe needle as the intermediate sliding valve advances toward the syringe needle.
  • the abutment portion and the slide portion are integrated with each other to form a slider, as described in claim 3.
  • the slider has a contact portion protruding forward of the injection valve needle side of the intermediate sliding valve body to be housed in the through-hole of the intermediate sliding valve body and to the plunger operating side with respect to the intermediate sliding valve body.
  • a side opening is provided on a surface of the slide portion, which is in contact with the inner wall surface of the through hole of the intermediate sliding valve body portion, and a front opening and a front opening opening in a space on the syringe needle side of the intermediate sliding valve.
  • a liquid passage communicating with the opening and the side opening is provided in the slide portion, the intermediate sliding valve body portion, or between the slide portion and the intermediate sliding valve body portion, and further, the slider is provided in the intermediate sliding valve body portion.
  • the side opening is sealed by the inner wall surface of the through hole of the intermediate sliding valve body, and when the slider is opened toward the plunger operation side with respect to the body of the intermediate sliding valve, the side opening is opened. It has a structure that is exposed to the medicine on the plunger operation side so that the medicine on the plunger operation side can be supplied to the syringe needle side of the intermediate sliding valve through the liquid passage hole.
  • Such a structure allows for a more reliable operation, a syringe with less dead space, and less residual drug solution.
  • the front opening that opens into the space on the syringe needle side of the intermediate sliding valve and the liquid passage that communicates with the front opening and the side opening are usually provided in the sliding portion. It may be provided on the body, or may be provided between the slide and the intermediate sliding valve body.
  • the syringe for a kit formulation of the present invention is such that, in the syringe for a kit formulation according to the third aspect, the side opening of the side surface of the slide portion is enlarged in the circumferential direction of the side surface of the slide portion. It has a part.
  • the plunger operation can be performed with a sufficiently light force even with a highly viscous drug solution, and accurate and safe injection can be performed.
  • a syringe for a kit formulation according to the fifth or fourth aspect wherein the slider has a syringe needle relative to an intermediate slide valve. It has a check part to prevent it from moving forward from the closed position with respect to the side.
  • a syringe for kit preparation according to claim 6, wherein the slide for the plunger is provided on the slide valve for the plunger, and the slider is provided with an intermediate slide. It has a recess corresponding to the amount of protrusion of the slider when it is opened, which slides toward the plunger operation side with respect to the valve train body.
  • the medicinal solution filled in the syringe can be injected without leaving it in the syringe, so that generally expensive medicinal solution is not wasted, and accurate injection of the injection amount is possible. .
  • At least the vicinity of the annular lip of the intermediate sliding valve for a syringe used, and furthermore, the portion that comes into contact with the slide portion, preferably the entire intermediate sliding valve, is a rubber or a lubricating component in which a lubricating component is chemically bonded. Consists of chemically bonded plastic It is more preferable that the lubricating component is a rubber chemically bonded in view of having elastomer properties.
  • the sliding properties of the intermediate sliding valve can be improved, and even with a syringe for kit preparation that has a larger number of sliding valves than an ordinary syringe, injection with a smooth and light force is performed.
  • a safe syringe can be obtained without using silicone oil, for which safety is partially questioned. The latter effect is remarkable in the preparation of a kit for a syringe in which the contact time between the drug and the sliding valve section is long.
  • the intermediate slide valve but also the slide valve for the plunger is made of rubber with lubricating components chemically bonded or rubber with chemical bonding. It is preferred that
  • Examples of the rubber to which the lubricating component is chemically bonded include nitrile rubber, hydrogenated nitrile rubber, ethylene-propylene-gen rubber, ethylene-propylene rubber, and petroleum rubber.
  • Examples of the plastics to which the lubricating component is chemically bonded include polyesters, polyamides, polypropylenes, polyolefins, and polyurethanes.
  • a lubricating component chemically bonded to rubber or plastic a synthetic oil-based lubricating material is desirable. Such materials include, for example, hydrocarbon-based, polyglycol-based, silicone-based, and fluorine-based materials. These lubricating components are derivatized and chemically bonded to the rubber or plastic. Since the amount of lubricating components chemically bonded has a large effect on lubricity, it is determined after various studies. There is a need to.
  • bonding may be performed by a general means such as an ordinary amide bond or an ester bond, but a group which reacts with a rubber-plastic cross-linking agent is introduced into a lubricating component in advance to perform cross-linking.
  • a method performed at the same time can be adopted.
  • a lubricating material with low reactivity such as fluororesin (polytetrafluoroethylene or a copolymer of perfluoroethylene and other comonomers)
  • an electrophilic reagent may be used. (Hindered phenols, Grignard reagents, etc.) can be added together with these lubricants during molding to form a chemical bond simultaneously with the crosslinking reaction.
  • the size of such a lubricant is preferably not less than 10 jwm and not more than 50 m in diameter.
  • the amount added is preferably from 5 to 60 parts by weight, more preferably from 10 to 50 parts by weight, based on 100 parts by weight of the base rubber component or plastic component.
  • a fluororesin and a silicone-based lubricant are used as a lubricating component
  • the sliding valve moves very smoothly and its movement starts smoothly, so that injection into a predetermined place such as intravenous injection becomes easy.
  • the injection volume may be adjusted according to the patient instead of injecting the entire injection solution in the cylinder. This has the effect of making injection extremely easy.
  • the fluororesin and the silicone-based lubricant which are lubricants, can be used alone as a lubricating component, but by using both at the same time, better lubricity can be obtained.
  • the electrophile must be compatible with the base rubber component or plastic component and must not cause obstacles
  • Such compounds include hindered phenols, for example, pentaerythrityl-tetrakis [3- (3,5-t-butyl-4-hydroxyphenyl) propionate], 2,2-thiodiethylenebis [3- ( 3,5-dibutyl-1-propylphenylpropionate], 2,2-thiobis (4-methyl-6-t-butylphenol), N, N'-bis [3- (3,5 —Di-t-butyl-1-hydroxyphenyl) propionyl] hydrazine and the like, and the Grignard reagent include those containing chlorine and iodine such as isopropylmagnesium chloride and isoo
  • electrophilic reagents are added in an amount of 0.1 to 10 parts by weight, particularly 0.2 to 5 parts by weight, based on 100 parts by weight of the rubber or plastic component as a base. .
  • These lubricants are mixed with an electrophile, a rubber component or a plastic component and a cross-linking agent.
  • injection molding is performed and the temperature is set to 140 ° G or more and 200 ° C or less in a mold.
  • a pressure of 2 OMPa or less By applying a pressure of 2 OMPa or less, if necessary, to a crosslinking treatment by applying a pressure of usually 2 OMPa or less, it is possible to obtain a sliding valve for a syringe in which a lubricating component is chemically bonded.
  • the method can be carried out by a method known as a method for crosslinking a rubber component or a plastic component.
  • modifiers antioxidants, cross-linking aids, processing aids, reinforcing agents, softeners, coloring agents, extenders, antioxidants, ultraviolet absorbers, etc.
  • additives for example, they need to have safety as raw materials for sliding valves for syringes.
  • a sliding valve for a syringe in which a lubricating component is integrated with a rubber component or a plastic component by chemical bonding has a sufficient lubricating property, but the lubricating component elutes or peels off / dissociates into a drug. Is completely eliminated. Also, since the sliding valve itself has lubricity, silicone coating There is no need to use it in combination with a treatment or a lubricating film, or the amount used in combination can be reduced, thus increasing safety.
  • Such a slide valve is also suitable as a slide valve for an ordinary syringe, but is particularly suitable as a slide valve for a syringe of a kit preparation having a long contact period with a drug solution.
  • the contact part, the slide part and the slider made of these must be made of a material that is not easily deformed. Such materials include metals and plastics. Then it is desirable to be plastic.
  • kits such as chemical resistance, non-elution, and sterilization resistance.
  • a plastic to which a lubricating component is chemically bonded may be used.
  • the liquid passage forming means must have a number corresponding to the number of intermediate sliding valves used at that time.
  • the material of the syringe used in the present invention those commonly used, that is, glass, polyolefin-based polymers such as polypropylene and amorphous polyolefin, and the like can be adopted.
  • plastic materials are preferred because they can be easily treated as medical waste, but they are compatible with the sterilization conditions of currently used autocrepes, are low in cost, and have stability. Considering such factors, it is desirable to use a glass syringe.
  • FIGS. 1 (a) and 1 (b) show an annular lip h1 (one in this example) which is in contact with the inner wall of the syringe cylinder and water-tightly divides the space on the syringe needle side and the space on the plunger operation side of the intermediate slide valve.
  • a through hole h3 that bypasses the annular lip and communicates the space between the syringe needle side and the plunger operation side space, sealing means for sealing the through hole, and the injection valve allows the intermediate sliding valve to move the intermediate slide valve toward the syringe needle side.
  • FIG. 1 (a) is a perspective view from the syringe needle side
  • FIG. 1 (b) is a perspective view from the plunger operation side.
  • reference numeral h2 denotes a plurality of holding portions that are in contact with the inner wall of the syringe barrel and hold the intermediate sliding valve so that the axis of the intermediate sliding valve coincides with the axis of the syringe barrel.
  • FIGS. 1 (c) and 1 (d) are views showing a slider I1 in which an abutment portion i1 and a slide portion i2 are integrated, and are respectively a perspective view from the syringe needle side and a plunger operation side. It is the perspective view seen from.
  • the length of the slider I 1 (the left and right length in the figure) is longer than the thickness of the intermediate sliding valve body H 1.
  • the length of the slider I 1 is longer than the thickness of the intermediate sliding valve body H 1, and the contact portion i 1 is connected to the syringe needle side of the intermediate sliding valve body H 1 (left in the figure). ) It protrudes forward, is housed in the through hole h3 of the intermediate sliding valve main body H1, and is slidable with respect to the intermediate sliding valve main body H1 toward the plunger operating side (right in the figure).
  • the sliding portion # 2 has a front opening which opens into the space on the syringe needle side of the intermediate sliding valve. # 3, the side opening i provided on the surface of the sliding portion i2 which is in contact with the inner wall surface of the main body through hole h3.
  • the side opening i4 is used for the drug on the plunger operation side.
  • the medicine exposed on the plunger operation side can be supplied to the syringe needle side of the intermediate slide valve Ha from the front opening i3 through the liquid passage hole i5.
  • the sealing means for sealing the through hole h3 is constituted by the side opening i4 and the wall surface of the intermediate sliding valve main body through hole h3. It can be seen that the seal release means for releasing the seal when reaching near the end point is constituted by the slider I1 in which the contact portion ⁇ 1 and the slide portion i2 are integrated.
  • the intermediate sliding valve body H1 projects forward of the syringe needle toward the syringe needle, and the intermediate sliding valve advances toward the syringe needle toward the bottom of the syringe needle or forward of the intermediate sliding valve Ha toward the syringe needle.
  • the sealing means is driven by an operation in which the contact portion i1 that contacts another intermediate slide valve and the contact portion ⁇ 1 move relative to the plunger operation side with respect to the intermediate slide valve main body Ha.
  • the sealing means and the sealing release means are constituted by the slide portion i2 for releasing the sealing of the through hole h3 by the sealing means.
  • FIG. 2 (a) is an enlarged view of the vicinity of the operation side of the intermediate slide valve Ha plunger in FIG. 1 (h).
  • the second agent behind the intermediate slide valve Ha passes through the side opening i4 and the liquid passage hole i5 of the slide portion i2 of the slider I1, and from the front opening i3 (not shown), the intermediate slide valve. It is possible to move ahead of Ha.
  • a normal slow injection operation as shown in FIG. 2 (a)
  • the side opening i4 is partially exposed to the second agent, the pressure of the second liquid decreases, and At the moment, the sliding operation of the intermediate sliding valve body H1 to the right in the figure stops.
  • the opening is kept small, and as a result, the pressure loss when the second liquid passes through the side opening i4 is large, so that the plunger operation becomes stiff and the subsequent injection operation becomes relatively difficult.
  • the plunger operation becomes stiff and the subsequent injection operation becomes relatively difficult.
  • the side opening i4 on the side surface of the slide portion i2 is enlarged in the circumferential direction of the slide portion 'i2 (two arrow directions in Fig. 2 (a)).
  • the part i6 may be provided on the side surface of the slide part i2.
  • the expanding portion 6 is groove-shaped and makes a full circumference in the circumferential direction on the side surface of the slide portion i2.
  • intermediate slide valve body H 1 By providing a non-return portion for preventing the slide portion i 2 from moving forward from the closed position to the syringe needle side with respect to the intermediate slide valve Ha (intermediate slide valve body H 1), This can be the case when the cap is filled with a vacuum for filling chemicals, when the operator operates the plunger to the suction side, or when abnormal vibrations occur during storage or transportation, or when the environment is sudden (such as temperature). The chemical solution before and after the intermediate slide valve was mixed even if Or the risk of inoperability can be prevented.
  • Fig. 2 shows an example in which a check part i7 having an outer diameter larger than the inner diameter of the through hole h3 of the intermediate sliding valve body is provided at the plunger operation side end of the slide part i2 as such a check part. This is shown in (c).
  • the check portion i7 is provided on the intermediate sliding valve main body H1 at the time of sealing before the sliding portion i2 slides toward the plunger operating side with respect to the intermediate sliding valve main body H1. It is designed to be completely stored in the check section storage section h4.
  • FIG. 2 (d) shows an example of a slide portion having a check portion i7 'of another shape.
  • the check part i 7 ′ is provided on the plunger operation side with a part that is one step thicker than the check part i 7 in FIG. 2 (c), and the enlarged part is stored in the check part storage part h 4.
  • the same members will be described with the same reference numerals.
  • the slider I2 shown in FIG. 3 (a) has a groove-shaped widened portion i6 that goes around the circumferential direction near the side opening i4.
  • the slider I3 shown in FIG. 3 (b) has a groove-shaped widened portion i6 that goes around the circumference in the vicinity of the side surface opening ⁇ 4. There is also a similar groove i8, and as a result, the contact area between the slider I3 and the inner wall of the through hole of the intermediate sliding valve body is reduced, and the slidability of the slider I3 is improved. .
  • the slider I4 in FIG. 3 (c) is another example in which the slidability is improved similarly to the slider I3.
  • FIGS. 4 (a) to (d) show other examples I5 to I8 of the slider.
  • the liquid passage hole # 10 communicating with the front opening i9 and the side opening i11 is constituted by the slide portion and the inner wall surface of the through hole of the intermediate sliding valve body (not shown).
  • These have a front opening i11 opening into the space on the syringe needle side of the intermediate sliding valve, and a fluid passage i10 communicating the front opening i11 and the side opening i9 with the slide part i2.
  • FIG. 5 (a) shows a slider I9 having a check portion i7.
  • FIG. 5 (b) shows a sliding valve main body HI (same as that used in FIG. 1) which constitutes the intermediate sliding valve Hb (see FIG. 5 (c)) together with the slider I9.
  • FIG. 6 (a) also shows a slider I 10 having a check portion i ⁇ .
  • FIG. 6 (b) shows the sliding valve main body H 1 ′ that constitutes the intermediate sliding valve H c (see FIG. 6 (c)) together with the slider I 10.
  • the through hole h 3 ′ of the sliding valve main body H 1 ′ is provided with a large diameter portion that can accommodate the check portion i 7.
  • a slider I11 having a tapered check portion i7 may be used.
  • FIG. 8 shows an example of a two-lip intermediate sliding valve.
  • the two-lip type intermediate sliding valve does not allow the chemical liquid to enter between these lips, so that the chemical liquid is not wasted and the filled chemical liquid can be used more effectively.
  • FIG. 8 (a) shows the sliding valve body H4 of the two-lip intermediate sliding valve.
  • two annular lips h1 are provided.
  • FIG. 8 (b) shows the slider I12 forming the intermediate sliding valve Hd together with the sliding valve body H4.
  • the slider I 1 2 is formed by an abutment portion i 1 and a slide portion i 2, and the side surface opening of the slide portion i 2 along with the expansion portion i 6 is provided on a surface of the intermediate slide valve body through hole h 3 which is in contact with the inner wall surface.
  • the side opening i4 is exposed to the medicine on the plunger operation side, and the medicine on the plunger operation side is injected into the intermediate slide valve through the above-mentioned liquid passage i5. It can be supplied to the cylinder needle side.
  • the slider I 12 is provided with a check part i 7.
  • Middle code 1 indicates a glass syringe (one-piece, normal shape) which is easy to sterilize and mass-produced at low cost.
  • lidocaine hydrochloride (infiltration anesthetic) liquid is filled as a first agent 5 in a watertight space formed by the injection cylinder 1 and the intermediate sliding valve Hd of this kit preparation.
  • sodium hyaluronate solution is filled as the second agent 6 in a watertight space formed by the injection cylinder 1, the intermediate sliding valve Hd, and the plunger sliding valve 2.
  • the injection needle connection portion 1a of the injection cylinder 1 is sealed by a cap 4 made of resin.
  • the cap 4 Prior to use of such a kit preparation, the cap 4 is removed as shown in FIG. 9 (b), and the injection needle 7 is attached to the injection needle connection portion 1a of the injection cylinder 1.
  • the plunger operation section 2a is operated at this stage to reduce the injection amount.
  • the injection needle 7 is pierced into the required injection site, and then the plunger operation section 2a is moved to the syringe needle side to inject the first agent 5.
  • the state immediately before the injection of the first agent 5 is completed when the intermediate sliding valve Hd moves within the syringe cylinder 1 and reaches the syringe needle side end point and the injection of the second agent 6 is shown in FIG. 9 (c). Show.
  • the slider I 12 of the intermediate sliding valve Hd which was initially in the closed state, slides to the open state shown in FIG. 9 (c), so that the rear of the intermediate sliding valve Hd
  • the second agent 6 can move to the front of the intermediate sliding valve Hd from the front opening i3 through the side opening i4 and the liquid passage hole i5 of the slider I11.
  • the plunger sliding valve 2 has the sliding portion i 2 of the slider I 12, which slides toward the plunger operating side with respect to the intermediate sliding valve body H 1, and the amount of protrusion of the sliding portion when opened (the 9 (See (d) in Fig. 9), the recess 2b is provided, so that the intermediate sliding valve main body H4 and the plunger sliding valve 2 are in close contact with each other. There is almost no residual liquid between 1 and the plunger sliding valve 2, and almost all of the second liquid can be injected.
  • the side opening i4, the liquid passage hole i5, and the front opening i3 need to be sufficiently thin, but the viscosity of the second liquid is high. In such a case, the pressure loss will be large, so it is necessary to design in consideration of the properties of the drug solution so as not to impede the injection operation.
  • the injection operation may be terminated in a state where the second agent 6 remains in the syringe 1.
  • the medicinal solution can be sequentially and reliably injected even if a conventional injection cylinder without special processing is used.
  • Kit preparation that can be injected sequentially without mixing three or more drugs Syringe (one first intermediate sliding valve located closest to the syringe needle inside the syringe barrel, and one or more second intermediate sliding valves located closer to the plunger operating side than the first intermediate sliding valve)
  • Syringe one first intermediate sliding valve located closest to the syringe needle inside the syringe barrel, and one or more second intermediate sliding valves located closer to the plunger operating side than the first intermediate sliding valve
  • the intermediate sliding valve Hd shown in Fig. 10 (a) is the same as the one used in Fig. 9 ⁇ : the intermediate sliding valve located closest to the syringe needle (hereinafter referred to as "the first intermediate sliding valve”).
  • the intermediate sliding valve of the present invention which enables sequential injection without mixing two agents, allows sequential injection without mixing three or more liquids without changing the design. It can be used as the first intermediate sliding valve in a syringe, and the intermediate sliding valve H d ′ (hereinafter referred to as “second intermediate sliding valve”) shown in FIG. This is an intermediate sliding valve located closer to the plunger operation side than the sliding valve.
  • the intermediate sliding valve Hd and the intermediate sliding valve Hd ' are arranged in a syringe 1 (a normal, integrally formed low-cost syringe) as shown in FIG. 10 (c). ing.
  • the intermediate sliding valve disposed closest to the syringe needle such as the intermediate sliding valve Hd is referred to as a “first intermediate sliding valve”.
  • first intermediate sliding valve the intermediate sliding valve disposed closest to the syringe needle
  • second intermediate sliding valve all of the intermediate sliding valves, such as the intermediate sliding valve Hd ', which are disposed on the plunger operation side of the first intermediate sliding valve are collectively referred to as "second intermediate sliding valve”.
  • the second intermediate sliding valve H d ′ is in contact with the inner wall of the injection cylinder and bypasses the annular lip h 1 and the annular lip h 1 which watertightly divides the injection needle side space and the plunger operation side space of the intermediate sliding valve.
  • a through-hole h3 ' that bypasses the annular lip h1 and communicates the space between the syringe needle side and the plunger operation side; sealing means for sealing the through-hole h3'; A seal releasing means for releasing the seal when the valve H d ′ reaches the end point of the injection needle on one needle side or in the vicinity of the end point, and the second intermediate sliding valve has the annular lip h 1 and
  • the intermediate sliding valve main body H 4 ′ having a through hole h 3 ′, the contact part i 1 and the sliding part i 2, and the sealing means and the sealing releasing means are directed toward the syringe needle of the intermediate sliding valve.
  • the sealing means is driven by the operation in which the contact part ⁇ 1 moves relatively to the plunger operation side with respect to the intermediate sliding valve body part '4', and the sealing of the through hole h3 'by the sealing means is released.
  • the contact portion i 1 ′ and the sliding portion i 2 ′ are integrated to form a slider I 1 2 ′, and the slider I 1 2 ′ is
  • the sliding valve body H 4 ′ is housed in the through hole h 3 ′ and is slidable to the plunger operating side with respect to the intermediate sliding valve body H 4 ′.
  • the length of the slider I 12 is almost equal to the thickness of the intermediate sliding valve main body H 4 ′, and it is located in front of the through hole h 3 ′ of the intermediate sliding valve main body H 4 ′.
  • a recess h5 having a large outer diameter of the slider of the intermediate sliding valve and having a size corresponding to a check portion protruding from the intermediate sliding valve toward the plunger operating side is provided.
  • the syringe shown in FIG. 10 (c) provided with one such first intermediate sliding valve Hd and one second intermediate sliding valve Hd ′ is the same as the syringe shown in FIG. It can be handled like a syringe.
  • Fig. 10 (c) shows a state in which the injection needle 7 is attached
  • Fig. 10 (d) shows a state in which the injection of the first liquid has been completed (the slider I12 has already been slid to the plunger operation side when opened).
  • Figure 10 (e) shows the state when the injection of the second liquid has been completed (when the slider I12 'abuts on the slider I12 and then slides to the plunger operation side, when opened)
  • the slide amount of the slide I12 'of the second intermediate slide valve Hd' to the plunger side is the slide amount of the slide I12 of the first intermediate slide valve Hd to the plunger side.
  • FIG. 10 (f) shows a state in which all injection operations have been completed.
  • the plunger sliding valve 2 and the second intermediate sliding valve Hd ' have a concave portion 2b corresponding to the plunger side slide amount of the slide I1 2' of the second intermediate sliding valve Hd '. Since there is no gap between the sliding valve H d ′, there is almost no residual drug solution in the syringe.
  • the total amount of liquid that can be injected decreases with an increase in the number of intermediate slide valves used.
  • the number of intermediate sliding valves to be used is two).
  • the first liquid is 20 mI of a water-soluble vitamin
  • the second liquid is 2 mI of a fat-soluble vitamin
  • the third liquid is 20 mI of glucose injection.
  • an annular lip which is in contact with the inner wall of the injection cylinder and divides the injection needle side space of the intermediate sliding valve and the plunger operation side space in a watertight manner, bypasses the annular lip and communicates the injection needle side space with the plunger operation side space.
  • a syringe comprising: a through-hole that seals the through-hole; sealing means for sealing the through-hole; and sealing release means for releasing the sealing when the intermediate sliding valve reaches the syringe needle side end point or near the end point during injection operation.
  • Fig. 11 (a) Another example He of the intermediate sliding valve is shown in Fig. 11 (a).
  • a through-hole h3 is provided at the center of the sliding valve main body H5, bypassing the annular lip, and communicating the space on the syringe barrel needle side with the space on the plunger operation side. It consists of a part with a small inner diameter on the cylinder needle side (small diameter part) h3a ⁇ and a thick part on the plunger operation side (large diameter part) h3b ".
  • a slider I13 (see FIG. 11 (b)) is housed as a sealing release means with its abutting portion i1 protruding toward the syringe needle.
  • a valve driving rod i2a is provided protrudingly on the plunger operation side of the slide part i2 of the slider I13, and the entire length of the slider I13 is longer than the small diameter part h3a ".
  • the valve driving rod i 2 a is configured to abut on a portion relatively close to the end, not on the center of the sealing valve ⁇ 12.
  • the sealing by the sealing valve i 12 between the injection needle side space of the intermediate sliding valve and the plunger operating side space is released, and the chemical liquid on the plunger operating side of the intermediate sliding valve He is transferred to the slider I 13. It becomes possible to move to the syringe needle side through the through hole i 13.
  • the sealing valve i 1 2 is fitted on the large-diameter portion h 3 b ”at the boundary (step) between the small-diameter portion h 3 a” and the large-diameter portion h 3 b ”of the through hole h 3”.
  • the shape of the slider I 13 can be freely changed as long as the above operation is possible, for example, so as to reduce the remaining liquid amount.
  • the syringe for kit preparation of the present invention has an intermediate slide valve inside the injection cylinder, wherein the intermediate slide valve is used for a syringe-type kit preparation in which at least a plunger operation side is filled with a drug solution.
  • An annular lip that contacts the inner wall of the injection cylinder and divides the injection needle side space and the plunger operation side space of the intermediate sliding valve in a watertight manner; and bypasses the annular lip to communicate the injection needle side space and the plunger operation side space.
  • the present invention is a syringe for a kit preparation having a simple and easy-to-manufacture structure capable of reliably and sequentially injecting a medicinal solution while using a conventional injection syringe having a conventional shape.
  • the intermediate slide valve for a syringe according to the present invention has an intermediate slide valve inside the syringe cylinder, and the intermediate slide valve for a syringe used for a syringe-type kit preparation in which a chemical solution is filled at least on the plunger operation side of the intermediate slide valve.
  • An annular lip which is in contact with the inner wall of the injection cylinder and which divides the injection needle side space and the plunger operation side space of the intermediate sliding valve in a watertight manner; and which bypasses the annular lip and connects the injection needle side space and the plunger operation side space.
  • a sealing means for sealing the through-hole, and the intermediate slide valve being connected to the syringe needle at the injection needle.
  • a simple and easy-to-manufacture structure capable of reliably injecting the chemical solution sequentially while using a conventional normal-shaped injection cylinder by using a structure having a seal releasing means for releasing the above-mentioned seal when reaching the point or the vicinity of the end point. Is an intermediate sliding valve for a syringe.
  • the kit preparation of the present invention has an intermediate slide valve inside the injection cylinder, and a syringe-type kit preparation in which at least the plunger operation side of the intermediate slide valve is filled with a drug solution, wherein the intermediate slide valve is: An annular lip which is in contact with the inner wall of the injection cylinder and divides the injection needle side space of the intermediate slide valve and the plunger operation side space in a watertight manner; a through hole which bypasses the annular lip and communicates the injection needle side space and the plunger operation side space
  • a sealing means for sealing the hole and the through hole and a sealing releasing means for releasing the sealing when the intermediate slide valve reaches the injection needle side end point or near the end point during the injection operation.
  • This is a syringe-type kit preparation having a simple and easy-to-manufacture structure capable of injecting a drug solution in a sequential manner without fail while using the normal-shaped injection cylinder.
  • FIG. 1 is a model diagram showing an example of an intermediate sliding valve Ha according to the present invention.
  • Slider I1 projects into the through hole h3 of the intermediate sliding valve main body H1 with the contact part i1 protruding toward the syringe needle side and housed to form the intermediate sliding valve Ha. It is the perspective view seen from the cylindrical needle side.
  • the plunger is operated in a state where the slider I1 is inserted into the through hole h3 of the intermediate sliding valve main body HI so that the contact portion i1 protrudes toward the injection needle and is housed to form the intermediate sliding valve Ha. It is the perspective view seen from the side.
  • FIG. 4 is a perspective view of the state in which the da I 1 has been slid relatively to the plunger operation side with respect to the intermediate sliding valve body H 1 as viewed from the syringe needle side.
  • FIG. 1 (h) is an enlarged view of the vicinity of the intermediate slide valve Ha plunger operation side in FIG. 1 (h).
  • (d) is a diagram showing a state in which check members having different shapes are provided.
  • (a)-(d) is a figure which shows the slider of another shape.
  • (b) is a view showing a sliding valve body H2.
  • (c) is a view showing an intermediate sliding valve Hb according to the present invention.
  • FIG. 7 is a view showing an intermediate sliding valve Hc according to the present invention.
  • FIG. 11 is a view showing a slider I 11 of another shape.
  • (a) is a view showing a sliding valve main body portion H4 constituting an intermediate sliding valve Hd according to the present invention together with a slider I12.
  • FIG. 3B is a view showing a slider I 12.
  • (c) is a view showing a state of the intermediate sliding valve Hd in a closed state before the slider I12 slides toward the plunger operation side with respect to the intermediate sliding valve body.
  • (d) is a view showing the state of the intermediate sliding valve Hd when the slider I12 is opened when the slider I12 slides toward the plunger operation side with respect to the intermediate sliding valve body.
  • (a) is a view showing a state before the start of use of a syringe-type kit preparation using the intermediate sliding valve Hd according to the present invention.
  • (d) is a diagram showing a state where injection by a syringe-type kit preparation using the intermediate sliding valve Hd according to the present invention has been completed.
  • FIG. 10 is an example of a syringe that can be sequentially injected without mixing the three liquids.
  • (a) is a view showing a first intermediate sliding valve Hd according to the present invention.
  • (b) is a view showing a second intermediate sliding valve H d 'according to the present invention.
  • (c) is a view showing a syringe that can be sequentially injected without mixing the three liquids.
  • (d) is a diagram showing a state in which the injection of the first liquid has been completed.
  • (e) is a diagram showing a state in which the injection of the second liquid has been completed.
  • (a) is a diagram showing an intermediate sliding valve He in which the sealing valve and the slider are separate members.
  • (a) is a diagram showing a state before starting use of a syringe-type kit preparation according to a conventional technique.
  • (c) is a diagram showing a state in which an injection needle has been attached just before starting use of a syringe-type kit preparation according to a conventional technique.
  • (a) is a diagram showing a state immediately before the injection operation of the first liquid is completed and the injection of the second liquid is started during use of the syringe-type kit preparation according to the conventional technique.
  • (b) is a diagram showing a state in which the injection with the syringe-type kit preparation according to the prior art has been completed.
  • (a) is a diagram showing another example of a syringe-type kit preparation according to the prior art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention porte sur un seringue utilisée pour des préparations de nécessaires d'injection et comprenant une valve coulissante intermédiaire accueillie dans le cylindre de la seringue, rempli d'un liquide médicinal au moins sur un côté d'actionnement du plongeur de la valve coulissante intermédiaire. Cette valve comprend une lèvre annulaire venant en contact avec la paroi interne du cylindre de la seringue afin de diviser l'espace de façon hermétique en un espace côté aiguille du cylindre et un espace côté actionnement plongeur ; un trou traversant contournant la lèvre annulaire et établissant une communication entre l'espace côté aiguille du cylindre et l'espace côté actionnement plongeur ; un dispositif de fermeture destiné à obturer le trou traversant et un dispositif de rupture du joint qui rompt le joint lorsqu'une injection oblige la valve coulissante intermédiaire à atteindre l'extrémité côté aiguille du cylindre ou sa proximité. Cet agencement permet de réaliser des injections successives, fiables, de liquide médicinal au moyen d'un cylindre spécifique de seringue.
PCT/JP2001/006782 2000-08-08 2001-08-07 Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection WO2002011793A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-240051 2000-08-08
JP2000240051 2000-08-08

Publications (1)

Publication Number Publication Date
WO2002011793A1 true WO2002011793A1 (fr) 2002-02-14

Family

ID=18731480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/006782 WO2002011793A1 (fr) 2000-08-08 2001-08-07 Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection

Country Status (1)

Country Link
WO (1) WO2002011793A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076534A1 (fr) * 2001-03-27 2002-10-03 Laboratoire De Contactologie Appliquee-Lca Seringue pour solutions viscoelastiques
JP2005027805A (ja) * 2003-07-10 2005-02-03 Nemoto Kyorindo:Kk 薬液シリンジ
WO2005072644A1 (fr) * 2004-02-02 2005-08-11 Bimeda Research & Development Limited Procede et dispositif de traitement du canal du trayon d'un animal
JP2005537106A (ja) * 2002-09-03 2005-12-08 メリディアン　メディカル　テクノロジーズ，インコーポレイテッド 薬物送達デバイス
JP2009523821A (ja) * 2006-01-19 2009-06-25 ポテンシア ファーマシューティカルズ， インコーポレイテッド 眼の障害のための注射可能複合療法
JP2010525868A (ja) * 2007-04-30 2010-07-29 メドトロニック ミニメド インコーポレイテッド リザーバ充填／気泡管理／注入媒体送給システムおよび該システムを用いる方法
JP2014041123A (ja) * 2012-08-21 2014-03-06 Astrium Gmbh 少なくとも十分に分離して物質を保管及び送出するための、特に宇宙空間における保管及び送出のための容器
US9180249B2 (en) 2004-02-02 2015-11-10 Bimeda Research & Development Limited Method and device
US9694134B2 (en) 2013-09-16 2017-07-04 Zoetis Services Llc Assembly for sequentially delivering substances, and associated methods
EP2432528A4 (fr) * 2009-05-22 2017-09-13 Michael P. Connair Système d'administration de stéroïde
EP3183015A4 (fr) * 2014-08-18 2018-05-02 Windgap Medical, Inc. Dispositif portable de mélange et d'administration de médicaments et procédés associés
US10293115B2 (en) 2014-12-05 2019-05-21 Elm-Plastic Gmbh Injector for administering a liquid or pasty substance, in particular a drug
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10875893B2 (en) 2012-11-15 2020-12-29 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
EP3881877A1 (fr) * 2020-03-17 2021-09-22 Becton Dickinson France Butoir pour un dispositif d'injection médical
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US11980742B2 (en) 2014-12-29 2024-05-14 Novo Nordisk A/S Drug delivery device with a hydraulic trigger mechanism
WO2024112625A1 (fr) * 2022-11-21 2024-05-30 Becton, Dickinson And Company Seringue d'administration séquentielle de médicament

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144551A1 (fr) * 1983-09-28 1985-06-19 Becton Dickinson and Company Assemblage de seringue pour médication à deux composants
WO1994012227A1 (fr) * 1992-12-01 1994-06-09 Tetsuro Higashikawa Seringue
JPH07136267A (ja) * 1993-11-17 1995-05-30 Arute:Kk ２室式容器兼用注射器
JPH08294532A (ja) * 1995-04-25 1996-11-12 Nissho Corp プレフィルドシリンジ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144551A1 (fr) * 1983-09-28 1985-06-19 Becton Dickinson and Company Assemblage de seringue pour médication à deux composants
WO1994012227A1 (fr) * 1992-12-01 1994-06-09 Tetsuro Higashikawa Seringue
JPH07136267A (ja) * 1993-11-17 1995-05-30 Arute:Kk ２室式容器兼用注射器
JPH08294532A (ja) * 1995-04-25 1996-11-12 Nissho Corp プレフィルドシリンジ

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001362B2 (en) 2001-03-27 2006-02-21 Laboratoire De Contactologie Appliquee-Lca Syringe for visco-elastic solutions
WO2002076534A1 (fr) * 2001-03-27 2002-10-03 Laboratoire De Contactologie Appliquee-Lca Seringue pour solutions viscoelastiques
JP2005537106A (ja) * 2002-09-03 2005-12-08 メリディアン　メディカル　テクノロジーズ，インコーポレイテッド 薬物送達デバイス
JP2005027805A (ja) * 2003-07-10 2005-02-03 Nemoto Kyorindo:Kk 薬液シリンジ
GB2429159B (en) * 2004-02-02 2008-10-29 Bimeda Res & Dev Ltd Method and device for treating a teat canal of an animal
GB2429159A (en) * 2004-02-02 2007-02-21 Bimeda Res & Dev Ltd Method and device for treating a teat canal of an animal
WO2005072644A1 (fr) * 2004-02-02 2005-08-11 Bimeda Research & Development Limited Procede et dispositif de traitement du canal du trayon d'un animal
EP2962660A1 (fr) * 2004-02-02 2016-01-06 Bimeda Research & Development Limited Dispositif de traitement d'un canal du trayon d'un animal
US9180249B2 (en) 2004-02-02 2015-11-10 Bimeda Research & Development Limited Method and device
US7828765B2 (en) 2004-02-02 2010-11-09 Bimeda Research & Development Ltd Method and device for administering two components into the teat canal of a non-human animal
US8353877B2 (en) 2004-02-02 2013-01-15 Bimeda Research & Development Limited Method for administering two components into the teat canal of a non-human animal
US9056076B2 (en) 2005-10-08 2015-06-16 Potentia Pharmaceuticals, Inc. Method of treating age-related macular degeneration comprising administering a compstatin analog
US10407466B2 (en) 2005-10-08 2019-09-10 Apellis Pharmaceuticals, Inc. Methods of selecting compstatin mimetics
JP2013155189A (ja) * 2006-01-19 2013-08-15 Potentia Pharmaceuticals Inc 眼の障害のための注射可能複合療法
JP2009523821A (ja) * 2006-01-19 2009-06-25 ポテンシア ファーマシューティカルズ， インコーポレイテッド 眼の障害のための注射可能複合療法
JP2010525868A (ja) * 2007-04-30 2010-07-29 メドトロニック ミニメド インコーポレイテッド リザーバ充填／気泡管理／注入媒体送給システムおよび該システムを用いる方法
EP2432528A4 (fr) * 2009-05-22 2017-09-13 Michael P. Connair Système d'administration de stéroïde
JP2014041123A (ja) * 2012-08-21 2014-03-06 Astrium Gmbh 少なくとも十分に分離して物質を保管及び送出するための、特に宇宙空間における保管及び送出のための容器
US11292815B2 (en) 2012-11-15 2022-04-05 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10875893B2 (en) 2012-11-15 2020-12-29 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10941184B2 (en) 2013-03-15 2021-03-09 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US11407789B2 (en) 2013-03-15 2022-08-09 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9694134B2 (en) 2013-09-16 2017-07-04 Zoetis Services Llc Assembly for sequentially delivering substances, and associated methods
EP3183015A4 (fr) * 2014-08-18 2018-05-02 Windgap Medical, Inc. Dispositif portable de mélange et d'administration de médicaments et procédés associés
EP3183020A4 (fr) * 2014-08-18 2018-05-02 Windgap Medical, Inc. Dispositif de mélange et d'administration de médicament portable et procédés associés
US10293115B2 (en) 2014-12-05 2019-05-21 Elm-Plastic Gmbh Injector for administering a liquid or pasty substance, in particular a drug
US11980742B2 (en) 2014-12-29 2024-05-14 Novo Nordisk A/S Drug delivery device with a hydraulic trigger mechanism
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11844841B2 (en) 2017-04-07 2023-12-19 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
EP3881877A1 (fr) * 2020-03-17 2021-09-22 Becton Dickinson France Butoir pour un dispositif d'injection médical
WO2021185810A1 (fr) * 2020-03-17 2021-09-23 Becton Dickinson France Bouchon pour un dispositif d'injection médical
CN115315283A (zh) * 2020-03-17 2022-11-08 贝克顿迪金森法国公司 用于医用注射装置的塞子
EP4382151A3 (fr) * 2020-03-17 2024-07-03 Becton Dickinson France Bouchon pour dispositif d'injection médical
WO2024112625A1 (fr) * 2022-11-21 2024-05-30 Becton, Dickinson And Company Seringue d'administration séquentielle de médicament

Similar Documents

Publication Publication Date Title
WO2002011793A1 (fr) Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US11389589B2 (en) Methods and devices for autoflush syringes
CN204446979U (zh) 用于建立无菌连接的装置和医疗设备
US8075547B2 (en) Autoflush syringe method
JP5431152B2 (ja) 注射器内に装備される摺動弁及び該摺動弁を装備した注射器
JP4682850B2 (ja) プレフィルドシリンジ
EP1113830B1 (fr) Cartouche d'injection sans aiguille
US10039884B2 (en) Clip syringe
EP2806918B1 (fr) Dispositifs pour seringues auto-rinçables
US20080171971A1 (en) Novel enhanced device and technique for mixing and dispensing a preserved agent
JP2007185319A5 (fr)
EP3681561B1 (fr) Capuchon coulissant de seringue pour remplissage et distribution séparés
JP2002172166A (ja) プレフィルドシリンジ
JP2002045422A (ja) キット製剤用注射器、通液路形成具及び注射器型キット製剤用中間摺動弁
JP2004129695A (ja) キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにキット製剤用注射筒の製造方法
JP2005131216A (ja) キット製剤用中間摺動弁、及び、キット製剤用注射筒
JP2004321826A (ja) キャップおよび既充填薬液容器
CN1207065C (zh) 带有预装填药筒的无针注射器
JP2020146523A (ja) 薬物搬送装置
JP2003299734A (ja) 注射器型キット製剤及びその製造方法
JP2006527625A (ja) 医療用ポンプ
WO2001047587A1 (fr) Vanne-tiroir de seringue et piston destine a une seringue pourvue de vanne-tiroir
JP2003144544A (ja) 医療用低速駆動装置
JP2004089222A (ja) 注射筒及び注射筒の製造方法、並びに、注射針接続部がシールされた注射筒の製造方法
JP2004283630A (ja) マルチ針付きホルダー

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR CA CN CO CZ ID IS JP KR PL SI SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002517125

Country of ref document: JP

122 Ep: pct application non-entry in european phase